المؤلفون: Julius Korsimaa, Martin Weber, Petteri Salminen, Joonas Mustonen, Denys Iablonskyi, Edward Hæggström, Arto Klami, Ari Salmi

المصدر: Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)

مصطلحات موضوعية: Medicine, Science

الوصف: Abstract We present a novel internet of things (IoT) sensing platform that uses helical propagation paths of ultrasonic guided waves (UGWs) for structural health monitoring. This wireless sensor network comprises multiple identical sensor units that communicate with a host PC. The units have dedicated hardware to both generate and receive ultrasonic signals, as well as RF signals for use in triggering the sensors. The system was developed for monitoring and sensing pipelines and similar structures in real-time to facilitate interactive sensing. For accurate sensing with a limited number of arbitrarily scattered sensors, we obtain information from all sensor pairs and analyze helical propagation paths in addition to the commonly used shortest paths. UGWs can propagate long distances along the walls of pipelines, and their propagation velocity depends directly on the thickness of the waveguide, and is affected by energy leakage and mass loading. In this paper, we evaluated the network by utilizing it to detect fouling. The network could be adapted for further ultrasonic measurement tasks, e.g., measuring wall thicknesses or monitoring defects with pulse-echo methods.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2045-2322Test

الوصول الحر: https://doaj.org/article/ac0e7d1f58f04bc085740f637d88a0b1Test

المؤلفون: Hanne Kuitunen, Marjukka Pollari, Milla E.L. Kuusisto, Peeter Karihtala, Jyrki Jauhiainen, Eija Korkeila, Roosa Enni Inkeri Prusila, Taru Tanhua, Sakari Kakko, Petteri Salmi, Aleksi Postila, Juan-Manuel Sancho, Esa Jantunen, Kaija Vasala, Taina Turpeenniemi-Hujanen, Outi Kuittinen, Santiago Mercadal, Ilja Nystrand, Susanna Tikkanen, Marc Sorigue

المصدر: British Journal of Haematology. 187:364-371

مصطلحات موضوعية: Adult, Male, Oncology, medicine.medical_specialty, Adolescent, Follicular lymphoma, Disease-Free Survival, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, Internal medicine, medicine, Humans, In patient, Registries, Lymphoma, Follicular, Aged, Retrospective Studies, Aged, 80 and over, business.industry, Incidence (epidemiology), Late effect, Neoplasms, Second Primary, Retrospective cohort study, Hematology, Middle Aged, medicine.disease, Confidence interval, Survival Rate, Standardized mortality ratio, Hematologic Neoplasms, 030220 oncology & carcinogenesis, Female, Rituximab, medicine.symptom, business, Follow-Up Studies, 030215 immunology, medicine.drug

الوصف: Follicular lymphoma (FL) is the most common indolent lymphoma. Currently there are many comparable treatment options available for FL. When selecting the most optimal therapy it is important to consider possible late effects of the treatment as well as survival. Secondary haematological malignancy (SHM) is a severe late effect of treatments, but the incidence of SHMs is still largely unknown. The goal of the present study was to determine the incidence of SHMs and how therapeutic decisions interfere with this risk. The study included 1028 FL patients with a median follow-up time of 5·6 years. The 5-year risk of SHM was 1·1% and the risk was associated with multiple lines of treatment (P = 0·016). The 5-year risk of SHM was 0·5% after the first-line treatment and 1·6% after the second-line. The standardized incidence ratio (SIR) was 6·2 (95% confidence interval 3·4-10·5) for SHM overall. This retrospective study found that the risk of SHM was low after first-line treatment in FL patients from the rituximab era. However, the risk of SHM increases with multiple lines of treatment. Therapeutic approaches should aim to achieve as long a remission as possible with first-line treatment, thereby postponing the added risk of SHM.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fab2ab1e0caa59dee30edc5be26d40eTest
https://doi.org/10.1111/bjh.16090Test

المؤلفون: Petteri Salmi, Hanne Kuitunen, Peeter Karihtala, Marjukka Pollari, Esa Jantunen, Jyrki Jauhiainen, Taina Turpeenniemi-Hujanen, Juan-Manuel Sancho, Aleksi Postila, Kaija Vasala, Sakari Kakko, Outi Kuittinen, Santiago Mercadal, Eija Korkeila, Milla E.L. Kuusisto, Marc Sorigue, Roosa Enni Inkeri Prusila, Taru Tanhua, Ilja Nystrand, Susanna Tikkanen

المصدر: Acta oncologica (Stockholm, Sweden). 58(11)

مصطلحات موضوعية: Oncology, Male, medicine.medical_specialty, Solid cancer, Population, Follicular lymphoma, MEDLINE, 030218 nuclear medicine & medical imaging, 03 medical and health sciences, 0302 clinical medicine, Sex Factors, Internal medicine, medicine, Humans, Radiology, Nuclear Medicine and imaging, In patient, education, Lymphoma, Follicular, Aged, Retrospective Studies, education.field_of_study, business.industry, Incidence (epidemiology), Incidence, Age Factors, Retrospective cohort study, Neoplasms, Second Primary, Hematology, General Medicine, Middle Aged, medicine.disease, Lymphoma, 030220 oncology & carcinogenesis, Female, business

الوصف: Introduction: Patients with follicular lymphoma (FL) have classically had a higher risk of solid cancers than the general population, but there is little data available in patients diagnosed and tr...

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2152ce59b4e55be7e541d46d3850c21Test
https://pubmed.ncbi.nlm.nih.gov/31368395Test

المؤلفون: Milla E.L. Kuusisto, Peeter Karihtala, Hanne Kuitunen, Taina Turpeenniemi-Hujanen, Susanna Tikkanen, Outi Kuittinen, Taru Tanhua, Kaija Vasala, Petteri Salmi, Marc Sorigue, Sakari Kakko, Aleksi Postila, Ilja Nystrand, Roosa Enni Inkeri Prusila, Esa Jantunen, Marjukka Pollari, Eija Korkeila

المصدر: Blood. 132:5330-5330

مصطلحات موضوعية: Oncology, medicine.medical_specialty, Chemotherapy, business.industry, medicine.medical_treatment, Immunology, Follicular lymphoma, Cell Biology, Hematology, medicine.disease, Biochemistry, Chemotherapy regimen, Lymphoma, Leukemia, hemic and lymphatic diseases, Acute lymphocytic leukemia, Internal medicine, medicine, Rituximab, business, Multiple myeloma, medicine.drug

الوصف: Introduction Follicular lymphoma (FL) is the most common indolent lymphoma. Majority of the patients with FL have a good respond to first-line treatment. Relapses are common and many patients need to be re-treated (Izutsu K. J Clin Exp Hematop 2014). Treatment results of indolent non-Hodgkin lymphomas have improved vastly in last decades. This is resulting from the use of therapeutic antibodies such as rituximab (Friedberg JW. Haematologica 2008). With improved survival the risk of secondary malignancies may be higher. Some of the regimens used in the treatment of FL, especially alkylating agents, have been associated with the risk of secondary hematological malignancies such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Incidence of secondary MDS/AML peaks 4-6 years after the initial treatment. Secondary MDS/AML have poor prognosis. The incidence of secondary hematological malignancies and the impact of various treatment regimens among different lymphomas is still largely unknown (Friedberg JW. Haematologica 2008). Data of 1045 patients with FL was collected to find out the incidence of secondary hematological malignancies. We also wanted to know if the incidence is related to certain types of treatment or chemotherapy regimens. Methods This is a retrospective registry study. Clinical data was collected from six hospitals in Finland and two hospitals in Spain. We analyzed clinical data from hospital records of all patients with FL diagnosed between 1997 and 2016. Information such as age, stage, details of treatment, possible relapses, current status and details about secondary hematological malignancy were investigated. Results Median follow-up time was 5.6 years. Baseline characteristics and treatment-related data are presented in Table 1. Altogether 984 of all patients received treatment for lymphoma and from all patients 80.1% received rituximab during treatment. In all patients the 1-year PFS was 92.1% and the 5-year PFS 59.8%. The 5-year DSS was 91.6% and the 5-year OS was 84.1%. The incidence of secondary hematological malignancies is presented in Figure 1a. From all patients 15 (1.4%) developed secondary hematological malignancy. There were 5 cases of MDS, 4 AML, 1 acute promyelosytic leukemia, 1 acute lymphoblastic leukemia, 1 chronic lymphosytic leukemia, 1 chronic myelosytic leukemia, 1 large granular lymphosytic leukemia and 1 myeloma. The 5-year risk for secondary hematological malignancy was 1.3% and the approximated 10-year risk was 3.0%. The risk of secondary hematological malignancy was associated with the number of treatment lines (p=0.039), Figure 1b. There was no statistically significant difference between different first-line chemotherapy regimens. However, there was a trend presenting higher risk, when using alkylating regimens in the first line. With CHOP-like treatment the 5-year risk was 1.1% and the approximated 10-year risk was 3.6%. Conclusions This is a retrospective study from rituximab era. The prognosis of follicular lymphoma is good with the current treatment methods and the risk of secondary hematological malignancy seems to be low. Due to low incidence, it seems, that it is not necessary to avoid chemotherapy in the fear of secondary hematological malignancies. However, multiple lines of treatment are associated with higher risk for secondary hematological malignancies. Therefore, the use of regimens with long remission, like rituximab maintenance, would probably reduce the risk of secondary hematological malignancies. Disclosures No relevant conflicts of interest to declare.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::8a742d0f77d61a27a27969a549ccc3c2Test
https://doi.org/10.1182/blood-2018-99-110129Test